GlaxoSmithKline plc (NYSE:GSK) saw a significant decrease in short interest in November. As of November 30th, there was short interest totalling 10,397,225 shares, a decrease of 22.3% from the November 15th total of 13,387,745 shares. Based on an average trading volume of 4,254,511 shares, the short-interest ratio is currently 2.4 days. Currently, 0.4% of the shares of the company are sold short.
GlaxoSmithKline (NYSE GSK) opened at $34.99 on Monday. GlaxoSmithKline has a twelve month low of $34.52 and a twelve month high of $44.53. The company has a debt-to-equity ratio of 2.96, a current ratio of 0.64 and a quick ratio of 0.44. The company has a market capitalization of $86,052.55, a price-to-earnings ratio of 12.41, a PEG ratio of 1.94 and a beta of 0.98.
The business also recently declared a quarterly dividend, which will be paid on Thursday, January 11th. Stockholders of record on Friday, November 10th will be issued a $0.5037 dividend. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.49. This represents a $2.01 dividend on an annualized basis and a dividend yield of 5.76%. The ex-dividend date is Thursday, November 9th. GlaxoSmithKline’s dividend payout ratio (DPR) is presently 163.12%.
In other GlaxoSmithKline news, major shareholder Plc Glaxosmithkline bought 428,571 shares of GlaxoSmithKline stock in a transaction dated Monday, November 6th. The stock was bought at an average cost of $14.00 per share, with a total value of $5,999,994.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 10.00% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. Parametric Portfolio Associates LLC raised its position in shares of GlaxoSmithKline by 6.8% in the third quarter. Parametric Portfolio Associates LLC now owns 1,452,468 shares of the pharmaceutical company’s stock worth $58,970,000 after buying an additional 92,125 shares in the last quarter. Shelton Capital Management raised its position in shares of GlaxoSmithKline by 73.5% in the third quarter. Shelton Capital Management now owns 28,331 shares of the pharmaceutical company’s stock worth $1,150,000 after buying an additional 12,000 shares in the last quarter. Steward Partners Investment Advisory LLC purchased a new stake in shares of GlaxoSmithKline in the third quarter worth $328,000. Belpointe Asset Management LLC purchased a new stake in shares of GlaxoSmithKline in the third quarter worth $204,000. Finally, Wealthcare Advisory Partners LLC raised its position in shares of GlaxoSmithKline by 1,982.8% in the third quarter. Wealthcare Advisory Partners LLC now owns 3,520 shares of the pharmaceutical company’s stock worth $143,000 after buying an additional 3,351 shares in the last quarter. 9.83% of the stock is owned by hedge funds and other institutional investors.
GlaxoSmithKline Company Profile
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.